MARLBOROUGH

LiquidStack to Showcase Immersion Cooling Technology at Cisco Live's Sustainability Zone

Retrieved on: 
Tuesday, May 28, 2024
Cisco, Immersion, Water, Network equipment provider

CARROLLTON, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- LiquidStack , a global leader in liquid cooling for data centers, today announced that it will showcase its advanced two-phase immersion cooling technology at Cisco Live , in the Cisco Sustainability Zone.

Key Points: 
  • CARROLLTON, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- LiquidStack , a global leader in liquid cooling for data centers, today announced that it will showcase its advanced two-phase immersion cooling technology at Cisco Live , in the Cisco Sustainability Zone.
  • Together with Cisco, LiquidStack is highlighting the superior cooling capabilities of immersion cooling for optical networking equipment, essential for supporting the growing needs of generative AI without compromising sustainability.
  • “We are thrilled at the opportunity to demonstrate our advanced two-phase immersion cooling technology alongside Cisco,” said Joe Capes, CEO, LiquidStack.
  • We invite all Cisco Live attendees to visit our demonstration in the Cisco Sustainability Zone and learn how LiquidStack is leading the way in sustainable data center cooling technology.

IPG Photonics Launches LightWELD® 2000 XR

Retrieved on: 
Thursday, May 23, 2024
Copper, Welding, TIG, IPG, IPG Photonics, XC, XR, Distortion, Titanium, IPGP, Oil, Metal fabrication

Fabricators will benefit from the increased processing speed and extended range of material thicknesses that LightWELD 2000 XR offers.

Key Points: 
  • Fabricators will benefit from the increased processing speed and extended range of material thicknesses that LightWELD 2000 XR offers.
  • LightWELD 2000 XR is the new, superior version to the existing LightWELD 1500 XR handheld laser welder and cleaner released in 2022.
  • The LightWELD 2000 XR offers 2 kilowatts of laser power, over 30% more than its predecessor.
  • LightWELD 2000 XR, all other LightWELD models and the LightWELD Cobot System are proudly made in the USA and are available direct from IPG and laser equipment distributors.

Phio Pharmaceuticals Secures New Investor

Retrieved on: 
Friday, May 17, 2024
Sale, Gene silencing

MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchase agreement with TRITON Funds.

Key Points: 
  • MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchase agreement with TRITON Funds.
  • Subject to the terms of the purchase agreement, TRITON will purchase up to approximately 18.8% of Phio’s common shares yielding gross proceeds of up to $621,000 to the Company.
  • Axel Olson, investment representative at TRITON Funds, remarked: “TRITON believes intelligent scientific innovation, when combined with exceptional management, is a proven strategy for success.
  • Our investment in Phio Pharmaceuticals, with its INTASYL™ technology, embodies this philosophy.”
    “We are very pleased to have TRITON Funds take a significant position in our Company,” said Robert Bitterman, Phio President and CEO.

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

Retrieved on: 
Thursday, May 16, 2024
NCT, Plasma, Health, Cytokine, Clinical trial, Trial of the century, Safety, Society, Research, PD-1, Carcinoma, Gene silencing, Vaccine

The data is being presented in three posters at the annual meeting of the Society for Investigative Dermatology (SID) this week in Dallas, Texas.

Key Points: 
  • The data is being presented in three posters at the annual meeting of the Society for Investigative Dermatology (SID) this week in Dallas, Texas.
  • PH-762 is an INTASYL compound that silences PD-1, a protein that inhibits T cells' ability to kill cancer cells.
  • The preclinical profile of PH-762 supports the ongoing clinical development of the compound for the treatment of cutaneous malignancies.
  • PH-762 is currently being studied in a US clinical trial to assess safety and efficacy in specific skin cancers (NCT 06014086).

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

Retrieved on: 
Wednesday, May 15, 2024
NCT, Gene silencing, Phio Pharmaceuticals, Patient, Merkel-cell carcinoma, Melanoma, Safety, News, Pharmaceutical industry

MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced progress on its Phase 1b clinical study for their lead compound PH-762.   Dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going.

Key Points: 
  • Dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going.
  • Phio’s Phase 1b study (NCT 06014086) is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma.
  • This study will assess the tumor response, and determine the recommended dose for further study of PH-762.
  • “This is exciting news for Phio and our lead compound PH-762 with the dosing of the 1st cohort completed, we look forward to advancing the study to bring an innovative treatment option to patients with skin carcinomas,” said Robert Bitterman, CEO of Phio Pharmaceuticals.

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2024
NK, Immunotherapy, Safety, Gene silencing, Rationalization, Research, Cell, Conference, Merkel-cell carcinoma, Downregulation and upregulation, NCT, Skin, Patient, Fox Business, Gene, Hyperpigmentation, Society, Patent, Melanoma, TYR, File, Angela Merkel, Vaccine

MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.

Key Points: 
  • MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and provided a business update.
  • At March 31, 2024, we had cash of $6.5 million as compared with $8.5 million at December 31, 2023.
  • Net loss was $2.2 million for the three months ended March 31, 2024 as compared with $3.6 million for the three months ended March 31, 2023.
  • The decrease in net loss was primarily due to the changes in research and development expenses, as described above.

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

Retrieved on: 
Thursday, May 9, 2024
Mortality, Risk, Prognosis, Research, Melanoma, Entrepreneurship, Patient, Health, Pharmaceutical industry

Melanoma is the leading cause of skin cancer-related deaths, with over 235,000 new diagnoses globally every year.

Key Points: 
  • Melanoma is the leading cause of skin cancer-related deaths, with over 235,000 new diagnoses globally every year.
  • Recent approvals of immune- and targeted therapies have greatly expanded the available treatment options for adjuvant therapy.
  • Nonetheless, a significant number of early-stage melanoma patients remain at high risk of relapse and mortality without access to such therapies.
  • As the majority of melanoma patients are diagnosed with early stage disease, there is a critical unmet medical need to identify those at-risk patients to potentially enable earlier access to life-saving therapeutic agents.

IPG Photonics Launches Cobot Laser Welding and Cleaning System

Retrieved on: 
Wednesday, May 8, 2024
IPG, IPGP, Safety, Motion, Welding, Human, Cobot, Studio, IPG Photonics, Metal fabrication

MARLBOROUGH, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (NASDAQ: IPGP), the world leader in fiber laser solutions, today announced the launch of an automated cobot laser welding and cleaning system for fabrication and manufacturing industries.

Key Points: 
  • MARLBOROUGH, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (NASDAQ: IPGP), the world leader in fiber laser solutions, today announced the launch of an automated cobot laser welding and cleaning system for fabrication and manufacturing industries.
  • The new cobot is a fully automated, laser welding and cleaning system which can be configured with any existing and future LightWELD® welding laser source.
  • IPG Photonics’ cobot laser production system makes automating welding jobs easy for fabricators regardless of experience with cobots or laser processing.
  • As with standalone LightWELD products, the system is also capable of switching between laser welding and laser cleaning in just seconds by simply changing the nozzle with no tools required.

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts

Retrieved on: 
Monday, May 6, 2024
Quality control, QC, Biology, Drug discovery

MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms.

Key Points: 
  • MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms.
  • “Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our ability to understand biology, disease progression, and patients’ response to therapy,” said Brian McKelligon, CEO of Akoya Biosciences.
  • Co-location of these functional areas enables a more rapid response to growing demand, simplifies manufacturing and supply chains, and facilitates gross margin improvement initiatives.
  • Now fully operational, the primary focus will be the manufacturing and QC of Akoya’s molecular barcoded antibodies and accompanying reagents.

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

Retrieved on: 
Monday, April 22, 2024
Gene silencing, Neoadjuvant therapy, Cell, Gene, Society, Melanoma, Clinical trial, TME, Pharmaceutical industry

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.

Key Points: 
  • -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma
    MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
  • mPH-762-mediated silencing of PH-762 within the TME may generate memory-specific T cells, promoting IFN-γ release in the TME
    These finding support the ongoing clinical trial of PH-762’s safety and efficacy as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma
    The data, authored by Melissa Maxwell, Linda Mahoney, and Dr. Mary Spellman, will be presented at the American Society of Gene and Cell Therapy (ASGCT) on May 8th in Baltimore, Maryland.
  • Presentation Details are as follows: